Medicine and Health
Neoadjuvant pembrolizumab, dabrafenib and trametinib in BRAFV600-mutant resectable melanoma: the randomized phase 2 Neo Trio trial
G. V. Long, M. S. Carlino, et al.
In a groundbreaking phase 2 trial, researchers explored the impact of combining targeted therapy with immunotherapy for patients with resectable stage III BRAFV600-mutant melanoma. Conducted by a team including Georgina V. Long and Matteo S. Carlino, the study uncovered crucial insights into treatment efficacy and recurrence rates, challenging the notion of enhanced benefits from combined therapies.
Related Publications
Explore these studies to deepen your understanding of the subject.
